tiprankstipranks
Advertisement
Advertisement

TECX Stock Latest News

Tectonic Therapeutic Completes Enrollment in Key TX45 Trial
Company AnnouncementsTectonic Therapeutic Completes Enrollment in Key TX45 Trial
15d ago
8K
TECX
Tectonic Therapeutic completes enrollment for APEX trial
PremiumThe Fly
Tectonic Therapeutic completes enrollment for APEX trial
15d ago
TECX
Tectonic Therapeutic upgraded to Strong Buy from Outperform at Raymond James
PremiumThe Fly
Tectonic Therapeutic upgraded to Strong Buy from Outperform at Raymond James
1M ago
TECX
Analyst Reaffirms Buy on Tectonic Therapeutic, Lifts Price Target to $88 on TX-45 Clinical Momentum and Expanded Market Opportunity
PremiumRatings
Analyst Reaffirms Buy on Tectonic Therapeutic, Lifts Price Target to $88 on TX-45 Clinical Momentum and Expanded Market Opportunity
2M ago
TECX
Tyler Van Buren Reiterates Buy on Tectonic as Advancing TX45 Program, Expanded Pipeline, and Strong Cash Runway Support Favorable Long-Term Risk‑Reward
PremiumRatings
Tyler Van Buren Reiterates Buy on Tectonic as Advancing TX45 Program, Expanded Pipeline, and Strong Cash Runway Support Favorable Long-Term Risk‑Reward
2M ago
TECX
Tectonic Therapeutic management to meet with Piper Sandler
PremiumThe FlyTectonic Therapeutic management to meet with Piper Sandler
2M ago
TECX
Tectonic Therapeutic Adds Veteran Banker to Board
Premium
Company Announcements
Tectonic Therapeutic Adds Veteran Banker to Board
2M ago
8K
TECX
Tectonic Therapeutic initiated with a Buy at Stifel
Premium
The Fly
Tectonic Therapeutic initiated with a Buy at Stifel
2M ago
TECX
Tectonic Therapeutic: Buy Rating on De‑Risked TX‑45 Phase 2 Program, Emerging TX2100 Pipeline, and Sufficient Cash Runway to 2026 Data Catalysts
PremiumRatings
Tectonic Therapeutic: Buy Rating on De‑Risked TX‑45 Phase 2 Program, Emerging TX2100 Pipeline, and Sufficient Cash Runway to 2026 Data Catalysts
4M ago
TECX
Tectonic Therapeutic Announces Leadership Transition and New Chair
PremiumCompany Announcements
Tectonic Therapeutic Announces Leadership Transition and New Chair
4M ago
8K
TECX
Tectonic Therapeutic chair Terry McGuire to retire, Francois Nader to succeed
PremiumThe Fly
Tectonic Therapeutic chair Terry McGuire to retire, Francois Nader to succeed
4M ago
TECX
Buy Rating on Tectonic: Differentiated TX45 Strategy, Favorable PK Profile, and Sufficient Cash Runway to Phase 2 Readouts
PremiumRatings
Buy Rating on Tectonic: Differentiated TX45 Strategy, Favorable PK Profile, and Sufficient Cash Runway to Phase 2 Readouts
5M ago
TECX
Tectonic Therapeutic price target lowered to $60 from $64 at Truist
PremiumThe FlyTectonic Therapeutic price target lowered to $60 from $64 at Truist
6M ago
TECX
Positive Outlook for Tectonic Therapeutic: Buy Rating Supported by Strategic Focus and Promising Trial Results
Premium
Ratings
Positive Outlook for Tectonic Therapeutic: Buy Rating Supported by Strategic Focus and Promising Trial Results
7M ago
TECX
Promising Outlook for Tectonic Therapeutic: Buy Rating Affirmed Amid Strong Financials and Progress in TX45 Trial
Premium
Ratings
Promising Outlook for Tectonic Therapeutic: Buy Rating Affirmed Amid Strong Financials and Progress in TX45 Trial
8M ago
TECX
Tectonic Therapeutic Reports Q3 2025 Financial Results
PremiumCompany Announcements
Tectonic Therapeutic Reports Q3 2025 Financial Results
8M ago
TECX
Tectonic Therapeutic reports Q3 EPS ($1.02), consensus ($1.05)
PremiumThe Fly
Tectonic Therapeutic reports Q3 EPS ($1.02), consensus ($1.05)
8M ago
TECX
Tectonic Therapeutic Reports Positive Phase 1b Trial Results
PremiumCompany Announcements
Tectonic Therapeutic Reports Positive Phase 1b Trial Results
8M ago
8K
TECX
Promising Phase 1b Trial Results and Market Expansion Justify Buy Rating for Tectonic Therapeutic
PremiumRatings
Promising Phase 1b Trial Results and Market Expansion Justify Buy Rating for Tectonic Therapeutic
8M ago
TECX
Tectonic Therapeutic Inc trading resumes
PremiumThe FlyTectonic Therapeutic Inc trading resumes
8M ago
TECX
Tectonic Therapeutic Inc trading halted, news pending
Premium
The Fly
Tectonic Therapeutic Inc trading halted, news pending
8M ago
TECX
Tectonic Therapeutic’s Promising Phase 2 Study on TX000045 for Pulmonary Hypertension
Premium
Company Announcements
Tectonic Therapeutic’s Promising Phase 2 Study on TX000045 for Pulmonary Hypertension
8M ago
TECX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >